Thursday, February 22, 2024 10:18:51 AM
Recent RNAZ News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/15/2024 09:23:29 PM
- TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 08:02:19 PM
- TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate • GlobeNewswire Inc. • 09/17/2024 11:00:00 AM
- TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 10:02:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:04:03 PM
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:45:28 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/26/2024 08:05:13 PM
- TransCode Therapeutics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 07/24/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 01:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 12:18:22 PM
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 07/23/2024 02:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 08:10:38 PM
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 07/22/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:16:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:15:52 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 12:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:06:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/10/2024 12:45:13 PM
- Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements • GlobeNewswire Inc. • 06/10/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/07/2024 08:00:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:00:20 PM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM
Future Hospitality Ventures Unveils Bold, New AI-Driven Initiative to Revolutionize the $300 Billion Hospitality Market • NGTF • Oct 16, 2024 7:07 AM
Kona Gold Beverages, Inc. Announces Strategic Progress and Corporate Evolution • KGKG • Oct 15, 2024 9:00 AM
One World Products Secures First Order for Hemp-Based Reusable Containers, Pioneers Renewable Materials for the Automotive Industry • OWPC • Oct 15, 2024 8:35 AM
ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • BURU • Oct 15, 2024 8:21 AM